Phase 3 randomized clinical trials of simufilam in mild-to-moderate Alzheimer’s disease

20261 citationsJournal Articlediamond Open Access

Authors

James W. Kupiec · Cassava Sciences (United States)

Anton P. Porsteinsson · University of Rochester

Raymond Scott Turner · Cambridge Cognition (United Kingdom)

Suzanne Hendrix · TetraLogic Pharmaceuticals (United States)

Craig Mallinckrodt · TetraLogic Pharmaceuticals (United States)

Arifulla Khan · Northwest Clinical Research Center

Ian Cohen

Abstract

Simufilam did not meet co-primary or secondary endpoints in these Phase 3 trials. Simufilam was safe and well tolerated. Trials registered at clinicaltrials.gov: NCT04994483 and NCT05026177.

Topics & Keywords

Phosphodiesterase function and regulation Biological Research and Disease Studies Alzheimer's disease research and treatments

Publication Details

Published in: The Journal of Prevention of Alzheimer s Disease

Volume 13, Issue 3, pp. 100469-100469

DOI: 10.1016/j.tjpad.2025.100469

Field-Weighted Citation Impact: 25.87

Command Palette

Phase 3 randomized clinical trials of simufilam in mild-to-moderate Alzheimer’s disease

Authors

Abstract

Topics & Keywords

Publication Details